SAGE1 and asthma: Also as PAGES, GALAII and SAGE, presented a higher exacerbation percentage before montelukast treatment, it is possible that those higher exacerbation percentage explain the high heterogeneity found between early-onset asthma cohorts and so the difference in the outcome.